Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Tyr Sphere

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Recruiting1
Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06941532Not ApplicableRecruiting

GMP Powdered Substitutes in PKU and TYR

NCT04761588Not ApplicableCompletedPrimary

Evaluation of TYR Sphere in France

NCT05910151Unknown

Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan

Showing all 3 trials

Research Network

Common Treatments

  • Tyr Sphere1
  • Obtaining Dry Blood Spots From Healthy Children Aged 8 Days 7 Years1
  • Obtaining Dry Blood Spots From Highrisk Childrens Aged 8 Days 7 Years1
  • Obtaining Dry Blood Spots From Healthy Children Aged 818 Years1
  • Obtaining Dry Blood Spots From Highrisk Childrens Aged 8 18 Years1

Active Sponsors

  • West Kazakhstan Medical University1
  • Nutricia UK Ltd1
  • Vitaflo International, Ltd1

Top Investigators

Related Conditions

  • Biotinidase Deficiency1
  • Malonylcoa Decarboxylase Deficiency1
  • 3hydroxy3methylglutarylcoa Lyase Deficiency1
  • Longchain 3hydroxyacylcoa Dehydrogenase Deficiency1
  • Argininosuccinic Aciduria1

Activity Timeline